BSD Medical is Now Pyrexar Medical

The complete line of BSD Hyperthermia products are availble thru Pyrexar Medical

Pyrexar Day is April 11th, 2016, at this year's ICHO in New Orleans.  We have some last-minute updates to our speaker schedule.  We will be hosting a "working lunch" starting at 12:15p.  Looking forward to seeing you at the event.

pyrexar day

Pyrexar Day Event Calendar - April 11, 2016
8:30a - 9:00a Meet and Greet - Refreshments
9:00a - 9:15a Welcome to Pyrexar Day - Mark Falkowski, CEO
9:15a - 10:00a Hyperthermia: A maturing technology moving toward more focused heating - Gerard Van Rhoon, PhD., Erasmus Hospital, Netherlands
10:00a - 10:45a Exploration of BSD-2000 System Applied to Clinical Treatment of Tumors – Dr. Sun Jinghua, Associate Professor, 2nd Affiliated Hospital of Dalian Medical University
10:45a - 11:30p Comprehensive Thermal Oncology Program at the University of Maryland: External, Interstitial, and Proton Thermal Therapy - Dr. Zeljko Vujaskovic, University of Maryland Medical Center
11:30p - 12:15p New Product Announcement & Presentation – Jason Ellsworth, VP Pyrexar Medical
12:30p – 1:15p Capacitive vs. Phased Array Hyperthermia - Paul Turner, CTO Pyrexar Medical
1:15p – 2:00p

Hyperthermia and Pancreatic Cancer; Adjunct to Radiation, Chemotherapy or Both - Dr. Curt Heese, Cancer Treatment Centers of America, Philadelphia

2:00p – 2:45p

Using Chemotherapy plus Hyperthermia for Advanced Liver Cancer - Xiao Shaowen, Associate Chief Physician. Beijing University

2:45p – 3:30p Quality Assurance of MR-Guided Deep Regional Hyperthermia in Children with Cancer – Dr. Ruediger Wessalowski Heinrich-Heine University Duesseldorf, Germany
3:30p – 4:15p Hyperthermia Adjunct to Chemotherapy Sarcoma Study - Dr. Rolf Issels, Ludwig-Maximilians-University of Munich
4:15p - 5:00p Hyperthermia with Proton Therapy: The thermoradiobiological basis and the early results from HYPROSAR study – Dr. Niloy Datta, Ksantonsspital Aarau
5:00p - 5:45p  Concepts For Future Deep Phased Array Systems - Paul Turner, CTO Pyrexar Medical
 6:00p  Pyrexar Award Presentation

This event is open to all Conference Attendees at no additional charge.  The event schedule above may change. For more information, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..

EVENT LOCATION: Intercontinental Hotel New Orleans, 444 St Charles Ave, New Orleans, LA 70130, USA

CE Celebration

The Pyrexar team is celebrating their new ISO 13485 Certification and CE re-certification today. ISO 13485 represents the requirements for a comprehensive quality management system for the design and manufacture of medical devices.  The ISO standard is also a required compliance to do business in the European Union. The CE mark,  a mandatory conformity marking for products sold within the European Economic Area (EEA) since 1985, allows Pyrexar to ship medical devices to any of the 27 Member States of the EU.  Much like the FDA clearance in the U.S., the CE mark is well respected and plays a key role in acceptance with regulatory agencies of other nations.

We are proud to announce two new additions to the ICHO/Pyrexar Day event calendar.

Curt HeeseDr. Curt Heese, board-certified radiation oncologist at Cancer Treatment Centers of America, Philadelphia. Dr. Heese will be sharing his experiences using Pyrexar Hyperthermia systems as an adjunct therapy to treat pancreatic cancer.

 

 

Niloy DattaDr. Niloy Datta, oncologist and prolific researcher in the field of hyperthermia at Kantonspital Aarau AG, Aarau, Switzerland.  Dr. Niloy Data will be sharing early results from a multi-institutional phase I/II clinical study "Hyperthermia and Proton Therapy in Unresectable Soft Tissue Sarcoma (HYPROSAR).

Our goal is to make hyperthermia the "standard of care" in the treatment of cancer.  Please join us in spreading the word.

 

pyrexar day

west indiesPlease welcome our new distribution partner,  Clinitech Company Ltd,  bringing the hyperthermia technologies into Cuba, the West Indies, Panama, and Venezuela.

Cancer deaths are high (138 per 100,000) in Cuba, according to World Life Expectancy.com, an organization that tracks death causality throughout the world.  Cuba's cancer stats rank 31 in the world, slightly lower than the UK, and several points higher than the USA.   According to a study in 2001-2003 by the National Cancer Registry, Lung, Prostate, Throat, and Colon had a high incidence in men, while Breast, Cervix, Lung, and Colon cancers were the most prevalent in women.

clinitech logo v2

Clinitech will be providing sales and service for the Pyrexar family of Superficial, Interstitial, and Deep Regional Hyperthermia devices. Leading their team is Ross University School of Medicine, Oncology Professor, Dr. Kamal Malaker, who has successfully used Hyperthermia technology in the treatment of cancer. “We are excited to bring this relatively under-explored, underutilized, well-proven, life-saving technology to the region,” says Wazir Mohammed, Clinitech’s President.

The distribution territory includes Antigua, Aruba, Bahamas, Barbados, Belize, Bermuda, Bonaire, British Virgin Islands, Cayman Islands, Cuba, Curacao, Dominica, Dominican Republic, Grenada, Guyana, Haiti, Jamaica, Montserrat, Panama, Puerto Rico, Saba, St. Ecstasies. St Kitts & Nevis, St Lucia, St Maarten, St Vincent. Suriname, Trinidad, and Tobago. Turks and Caicos. US Virgin Islands (St. Thomas, St. Croix, St John), Venezuela. Visit the "How to Buy" page for contact information.

"Pyrexar must continue our expansion to ensure our cancer-fighting system is offered worldwide, to all cancer patients" - Mark Falkowski, CEO.